Merck responds to Arcoxia approvable letter

James G. Dickinson

January 01 2007

Merck has responded to an FDA “approvable” letter for Arcoxia (etoricoxib), an investigational selective Cox-2 inhibitor, with results of the ...

Your Name: *

Your Email Address: *

Recipient(s) Email Address: *

(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)

Subject:*

Your message:

Send Me A Copy

The e-mail address(es) that you supply to use this service will only be used to send the requested article.